Tag: Eli Lilly
-
Donanemab slowed memory decline by 35%, disease progression by 39%, in Alzheimer’s trial
Patients who received Eli Lily’s monthly donanemab infusion in an 18-month study demonstrated a 35% slower decline in memory, thinking, and ability to perform activities of daily living, and were 39% less likely to progress to the next stage of the disease. Brain plaque was also reduced significantly. The risk of the drug is brain…